Results 161 to 170 of about 4,565 (192)
Some of the next articles are maybe not open access.
Brigatinib: First Global Approval
Drugs, 2017Brigatinib (ALUNBRIG™) is a small molecule antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company). In April 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-positive metastatic non-small cell lung ...
openaire +2 more sources
Brigatinib Effective in ALK+ NSCLC
Cancer Discovery, 2017Abstract Results from a phase I/II trial indicate that the investigational ALK inhibitor brigatinib is active in patients with ALK-rearranged non–small cell lung cancer. Patients who had previously received crizotinib—as well as those who hadn't—responded to the drug, which was also active in patients with brain metastases.
openaire +2 more sources
BRIGATINIB INDUCED PHOTOSENSITIVITY
Annals of Allergy, Asthma & Immunology, 2022C. Yie +3 more
openaire +1 more source